LDMP regulatory update

FDA accepted for review an NDA from Hisamitsu's Noven Pharmaceuticals Inc. for low-dose paroxetine mesylate to treat vasomotor symptoms associated with menopause. The PDUFA date is June 28, 2013. FDA...